SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-041328
Filing Date
2023-11-14
Accepted
2023-11-14 17:25:33
Documents
69
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1880555
2 ex10-2.htm EX-10.2 15992
3 ex10-3.htm EX-10.3 16909
4 ex10-4.htm EX-10.4 31732
5 ex10-5.htm EX-10.5 19109
6 ex31-1.htm EX-31.1 18764
7 ex31-2.htm EX-31.2 18953
8 ex32-1.htm EX-32.1 7606
9 ex32-2.htm EX-32.2 7725
  Complete submission text file 0001493152-23-041328.txt   9007449

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE mymd-20230930.xsd EX-101.SCH 55187
11 XBRL CALCULATION FILE mymd-20230930_cal.xml EX-101.CAL 51167
12 XBRL DEFINITION FILE mymd-20230930_def.xml EX-101.DEF 281456
13 XBRL LABEL FILE mymd-20230930_lab.xml EX-101.LAB 486745
14 XBRL PRESENTATION FILE mymd-20230930_pre.xml EX-101.PRE 379523
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1689800
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 231408076
SIC: 2835 In Vitro & In Vivo Diagnostic Substances